Загрузка...
Population Pharmacokinetic Analysis of Raltegravir Pediatric Formulations in HIV-infected Children 4 weeks to 18 years of age
P1066 is an open-label study of raltegravir in HIV+ youth, ages 4 weeks-18 years. Here we summarize P1066 pharmacokinetic (PK) data and a population PK model for the pediatric chewable tablet and oral granules. Raltegravir PK parameters were calculated using non-compartmental analysis. A two-compart...
Сохранить в:
| Опубликовано в: : | J Clin Pharmacol |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4572519/ https://ncbi.nlm.nih.gov/pubmed/25753401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.493 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|